

FAST FACTS

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study

Eligibility Criteria

1. Step 0 Eligibility Criteria

- a. Age $\geq$ 18 years old
- b. Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) that fits into any one of the following categories:
 - i. Patient is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) for metastatic cancer. Eligible treatment types are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGF-R inhibitor), endocrine therapy, or radiation therapy; or
 - ii. Patient is receiving adjuvant treatment for non-metastatic (Stage I-III) cancer and has received intravenous chemotherapy, immunotherapy, targeted therapy, or radiation therapy within the past 6 weeks; or
 - iii. Patient has received an allogenic stem cell transplant or CAR-T cell or other modified cellular therapy at any time; or
 - iv. Patient is currently receiving treatment or prophylaxis for Graft vs. Host Disease; or
 - v. Patient has received an autologous bone marrow transplant within the past 2 years.
- c. Testing for SARS CoV-2
 - i. Patient must be undergoing or have undergone testing for SARS CoV-2. Patients with prior negative SARS CoV-2 test(s) are eligible if they are being tested again.
Patients with prior positive SARS CoV-2 test(s) more than 14 days prior to enrollment are not eligible.
- d. HIV-infected patients are eligible
- e. Patients with brain metastases are eligible
- f. Co-enrollment on other clinical trials (for cancer or for COVID-19) is allowed.

2. Step 1 Eligibility Criteria

- a. Positive SARS CoV-2 test within the 14 days prior to enrollment to Step 1
Patient must have a documented positive SARS CoV-2 test. The positive test results must have been received no earlier than 14 days prior to enrollment to Step 1.
The test must have been ordered by a doctor's office, hospital, or department of public health.
Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the SARS CoV-2 test.

SCHEMA

